Wei, Danfeng
Hamblin, Michael R
Wang, Hao
Fekrazad, Reza
Wang, Chengshi
Wen, Xiang
Funding for this research was provided by:
the Science and Technology Department of Sichuan Province (2022NSFSC1414)
National Natural Science Foundation of China (81903226)
Article History
Received: 20 February 2024
Accepted: 26 June 2024
First Online: 5 July 2024
Declarations
:
: All methods were carried out in accordance with relevant guidelines and regulations. All animal experiments were approved by the Animal Care and Use Committee of West China Hospital, Sichuan University (No.20220118002). All experiments were performed in compliance with the ARRIVE guidelines.
: Not applicable.
: MRH declares the following potential conflicts of interest. Scientific Advisory Boards: Transdermal Cap Inc, Cleveland, OH; Hologenix Inc. Santa Monica, CA; Vielight, Toronto, Canada; JOOVV Inc, Minneapolis-St. Paul MN; Sunlighten, Kansas City, MO; PBM Healing International, Hong Kong. Consulting; USHIO Corp, Japan; Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany; Klox Asia, Guangzhou, China. Stockholding: Niraxx Light Therapeutics, Inc, Irvine CA; JelikaLite Corp, New York NY; Danvantar Biophotonics Oy, Helsinki, Finland. The other authors declare that they have no competing interests.